CTRI/2010/091/001049Not Applicable2 期
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
试验速览
- 阶段
- 2 期
- 状态
- Not Applicable
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
- •2.HIV 1 RNA viral load of greater then 500 copies/mL.
- •3.Negative urine pregnancy test.
排除标准
- •1. Suspected or documented active, untreated HIV-1 related opportunistic infection or other condition requiring acute therapy at the time of randomization.
- •2. Subjects with acute Hepatitis B and/or C within 30 days of randomization.
- •3. Previous use of Darunavir or etravirine
研究者
相似试验
进行中（未招募）
不适用
A study comparing different formulations of Meningococcal C conjugate vaccine, one of which is a newly manufactured liquid formulation of the same vaccine. This study will be conducted in 12-23 months old healthy children who will be randomly vaccinated with one of vaccine formulations in healthcare institutes.Prevention of meningococcal disease caused by serogroup C Neisseria meningitidis by evaluating the immunogenicity, tolerability, and safety of a liquid formulation of Novartis meningococcal C conjugate vaccine (MenC-CRM liquid) and of the lyophilized MenC-CRM vaccine produced with drug substance manufactured at Rosia, Italy, in comparison to the lyophilized MenC-CRM vaccine produced with drug substance manufactured at Emeryville, USA (Menjugate Kit).MedDRA version: 15.0Level: LLTClassification code 10036897Term: Prophylactic vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-000395-34-PLovartis Vaccines and Diagnostics S.r.l.
进行中（未招募）
不适用
A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's DiseaseCrohn's diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2008-004919-36-DKAbbott225
进行中（未招募）
不适用
A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's DiseaseCrohn's diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2008-004919-36-SEAbbott225
进行中（未招募）
不适用
A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's DiseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseCrohn's diseaseEUCTR2008-004919-36-ATAbbott225
进行中（未招募）
不适用
A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's DiseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseCrohn's diseaseEUCTR2008-004919-36-BEAbbott225